How to decide on the optimal duration of anticoagulatn therapy in carriers of the factor V Leiden mutation
Thromb Haemost
.
2000 Nov;84(5):740-1.
Authors
S Middeldorp
1
,
H R Büller
Affiliation
1
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. S.Middeldorp@amc.uva.nl
PMID:
11127847
No abstract available
Publication types
Comment
MeSH terms
Anticoagulants / administration & dosage*
Decision Making
Factor V / genetics*
Heterozygote
Humans
Mutation
Substances
Anticoagulants
factor V Leiden
Factor V